After Shuttering Genomics Division, Tapestry Risks Being Delisted from Nasdaq

Mar 07, 2005

NEW YORK, March 7 (GenomeWeb News) - Tapestry Pharmaceuticals, formerly known as NaPro BioTherapeutics, is in danger of being delisted to the Nasdaq Small-Cap Market for failing to keep its share price above $1 for 30 consecutive trading days, according to a news report.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Push for Predictive Genetic Tests

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

Gene-Editing Registry Proposed

A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.

Sneaking Out of the Lab

Vox writes that lab mishaps involving pathogens are quite common.

This Week in Genome Biology

In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.

Menu